A 26-week liraglutide study did not reduce amyloid levels or improve cognition, though it preserved how the brain uses glucose
Comorbidity Profiles and Cardiometabolic Health Patients with type 2 diabetes, hypertension, or dyslipidemia represent a high-priority candidacy group, as GLP-1 medications provide dual benefit: weight reduction and direct cardiovascular protection
And stay tuned for our fourth and final video of this series, which will be on the long term results of GLP
Pylori infections (18) Small intestinal bacterial overgrowth (19) Gastroparesis (20) Small fungal bacterial overgrowth Intestinal dysbiosis The presence of any of these gut conditions can negatively impact your immune system and may make your Hashimotos worse
Step 3: Identify your likely maintenance dose Based on your goals and body weight: Moderate weight loss, lighter body weight: 4 to 8 mg Moderate weight loss, heavier body weight: 8 mg Aggressive weight loss, any body weight: 8 to 12 mg Metabolic health focus: 4 to 8 mg Maximum fat loss with muscle preservation: 4 to 8 mg with high protein intake Step 4: Establish your monitoring protocol At minimum, track weekly body weight (same time, same conditions), side effect type and severity, daily caloric and protein intake, hydration status, and energy levels
This addition is particularly significant for researchers interested in the thermogenic properties of glucagon and how it might influence hepatic lipid metabolism alongside insulinotropic pathways
